I

Intercept Pharmaceuticals Inc
F:I4P

Watchlist Manager
Intercept Pharmaceuticals Inc
F:I4P
Watchlist
Price: 17.52 EUR Market Closed
Market Cap: 732.8m EUR
Have any thoughts about
Intercept Pharmaceuticals Inc?
Write Note

Intercept Pharmaceuticals Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Intercept Pharmaceuticals Inc
Accounts Payable Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
I
Intercept Pharmaceuticals Inc
F:I4P
Accounts Payable
$10.3m
CAGR 3-Years
-13%
CAGR 5-Years
8%
CAGR 10-Years
7%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$30.5B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$18.9B
CAGR 3-Years
153%
CAGR 5-Years
80%
CAGR 10-Years
35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$3.6B
CAGR 3-Years
205%
CAGR 5-Years
108%
CAGR 10-Years
58%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$497.3m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
27%

See Also

What is Intercept Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
10.3m USD

Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Accounts Payable amounts to 10.3m USD.

What is Intercept Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
7%

Over the last year, the Accounts Payable growth was -52%. The average annual Accounts Payable growth rates for Intercept Pharmaceuticals Inc have been -13% over the past three years , 8% over the past five years , and 7% over the past ten years .

Back to Top